Transcatheter Technologies GmbH
Transcatheter Technologies GmbH said it raised the 2nd tranche in its Series B round for its 3rd-generation replacement heart valve.
The tranche takes the German transcatheter aortic heart implant developer’s total raise to nearly $7.2 million, a spokesman told MassDevice.com this morning.
Transcatheter Technologies GmbH touted 6-month results from a pilot study of its Trinity transcatheter aortic valve implantation system, reporting no instances of valve leakage.
German device maker Transcatheter Technologies GmbH said it finished durability-testing Trinity transcatheter aortic valve implantation system.
The company expects Trinity to be “the world’s 1st ‘truly repositionable'” replacement aortic valve. The device was put through 600 million cycles, or around 15 years, of durability testing by an independent lab, which reported that the device far exceeded minimum standards, according to a press release.
Emerging medical device maker Transcatheter Technologies GmbH unveiled an early look at clinical results for its 3rd-generation Trinity transcatheter aortic valve implantation platform, which the company calls "the world’s 1st ‘truly repositionable’ and, therefore, best TAVI system."
MASSDEVICE ON CALL — Germany-based medical device company Transcatheter Technologies GmbH is making a bold stride into the transcatheter aortic valve implantation space, announcing 1st-in-man implantation of a device it says it intends to be the "the world’s best repositionable heart valve."